Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

被引：7

作者：

Acheampong, Desmond O. ^{[1
]}

Adokoh, Christian K. ^{[2
]}

Ampomah, Paulina ^{[1
]}

Agyirifo, Daniel S. ^{[3
]}

Dadzie, Isaac ^{[4
]}

Ackah, Francis A. ^{[1
]}

Asiamah, Ernest A. ^{[2
]}

机构：

[1] Univ Cape Coast, Sch Allied Hlth Sci, Dept Biomed Sci, Cape Coast, Ghana

[2] Univ Cape Coast, Sch Biol Sci, Dept Forens Sci, Cape Coast, Ghana

[3] Univ Cape Coast, Sch Biol Sci, Dept Mol Biol & Biotechnol, Cape Coast, Ghana

[4] Univ Cape Coast, Sch Allied Hlth Sci, Dept Med Lab Technol, Cape Coast, Ghana

来源：

PROTEIN AND PEPTIDE LETTERS | 2017年 / 24卷 / 05期

关键词：

Antibody; bispecific antibody (BsAb); immunotherapeutic agent; cancer therapy; diabody; antitumor; GROWTH-FACTOR RECEPTOR; ENHANCED ANTITUMOR-ACTIVITY; IN-VIVO; MASS-SPECTROMETRY; TARGETED THERAPIES; TRANSGENIC MOUSE; TYROSINE KINASE; BINDING DOMAINS; HALF-LIFE; HUMAN-IGG;

D O I：

10.2174/0929866524666170120095128

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.

引用

页码：456 / 465

页数：10

共 84 条

[1] Monoclonal antibody therapy of cancer [J].

Adams, GP ;

Weiner, LM .

NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157

[2] High-throughput screening of single-chain antibodies using multiplexed flow cytometry [J].

Ayriss, Joanne ;

Woods, Travis ;

Bradbury, Andrew ;

Pavlik, Peter .

JOURNAL OF PROTEOME RESEARCH, 2007, 6 (03) :1072-1082

[3] Bispecific T-Cell Engaging Antibodies for Cancer Therapy [J].

Baeuerle, Patrick A. ;

Reinhardt, Carsten .

CANCER RESEARCH, 2009, 69 (12) :4941-4944

[4] Bispecific human IgG by design [J].

Carter, P .

JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 248 (1-2) :7-15

[5] Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma [J].

Castellone, M. D. ;

Laukkanen, M. O. ;

Teramoto, H. ;

Bellelli, R. ;

Ali, G. ;

Fontanini, G. ;

Santoro, M. ;

Gutkind, J. S. .

ONCOGENE, 2015, 34 (13) :1679-1687

[6] Antibody engineering and its applications in tumor targeting and intracellular immunization [J].

Chames, P ;

Baty, D .

FEMS MICROBIOLOGY LETTERS, 2000, 189 (01) :1-8

[7] Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future [J].

Chen, Lieping ;

Han, Xue .

JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) :3384-3391

[8] A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity [J].

Chen, Zhiguo ;

Xie, Wei ;

Acheampong, Desmond Omane ;

Xu, Menghuai ;

He, Hua ;

Yang, Mengqi ;

Li, Chenchen ;

Luo, Chen ;

Wang, Min ;

Zhang, Juan .

CANCER BIOLOGY & THERAPY, 2016, 17 (02) :139-150

[9]

Cheung N-k, 2016, Book Anti-GD2 Antibodies. City: US Patent, Patent No. [20,160,176,981, 20160176981]

[10] A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates [J].

Chichili, Gurunadh R. ;

Huang, Ling ;

Li, Hua ;

Burke, Steve ;

He, Leilei ;

Tang, Qin ;

Jin, Linda ;

Gorlatov, Sergey ;

Ciccarone, Valentina ;

Chen, Francine ;

Koenig, Scott ;

Shannon, Michele ;

Alderson, Ralph ;

Moore, Paul A. ;

Johnson, Syd ;

Bonvini, Ezio .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (289)

← 1 2 3 4 5 6 7 8 9 →